Tyrosinase-derived peptide-MHC complex (Tyrosinase-MHC)

Tyrosinase-derived peptide antigens presented on MHC molecules represent a critical class of tumor-associated antigens (TAAs) primarily utilized in the immunotherapy of melanoma. Tyrosinase is a rate-limiting enzyme in melanin biosynthesis, and while it is expressed in normal melanocytes, it is significantly overexpressed in malignant melanoma cells. Specific peptides derived from the tyrosinase protein, such as the widely studied Tyrosinase 369-377 (YMDGTMSQV) fragment, are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, most notably HLA-A*02:01. These peptide-MHC (pMHC) complexes serve as the primary recognition signal for the T-cell receptor (TCR) of cytotoxic CD8+ T-cells. Therapeutic strategies targeting these complexes include peptide-based vaccines, engineered TCR-T cell therapies, and bispecific T-cell engagers (BiTEs) designed to redirect the immune system to eliminate tumor cells. However, because tyrosinase is also present in healthy skin and ocular melanocytes, targeting these antigens can lead to autoimmune side effects, such as vitiligo or uveitis, which are often monitored as indicators of treatment efficacy.

Other names

Tyrosinase-derived epitopesTyrosinase-HLA-A*02:01 complexMelanoma-associated antigen tyrosinaseTyrosinase peptide-HLA complexpMHC (Tyrosinase)

T-cell receptor (TCR) binding and activation, induction of cytotoxic T-lymphocyte (CTL) response, and antibody-mediated cellular cytotoxicity (ADCC) via TCR-mimetic antibodies.